The path is most likely through reliable structure prediction of drug targets. That would open up rational drug design projects that may have previously been impossible. The only problem is that experimental structure determination is so good in pharma, that it's hard to compete. For example, on a structure-enabled project, it may be possible to experimentally solve multiple high-resolution 3D models per week with an order of magnitude higher accuracy than predicted models. Once you can routinely get structures, there's still the rest of the drug discovery pipeline left to go.

It’s a fairly direct path, since computational drug discovery relies heavily on protein folding predictions.